RemeGen Co (HKSE:09995) Price-to-Operating-Cash-Flow : (As of Jan. 18, 2025)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Price-to-Operating-Cash-Flow?

As of today (2025-01-18), RemeGen Co's share price is HK$12.32. RemeGen Co's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-3.23. Hence, RemeGen Co's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for RemeGen Co's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 6 years, RemeGen Co's highest Price-to-Operating-Cash-Flow Ratio was 117.45. The lowest was 39.88. And the median was 71.75.

HKSE:09995's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 23.53
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

RemeGen Co's Cash Flow from Operations per share for the six months ended in Jun. 2024 was HK$-1.65. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-3.23.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -16.70% per year.

During the past 6 years, RemeGen Co's highest 3-Year average Operating Cash Flow per Share Growth Rate was -16.70% per year. The lowest was -59.20% per year. And the median was -37.95% per year.

RemeGen Co Price-to-Operating-Cash-Flow Historical Data

The historical data trend for RemeGen Co's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Price-to-Operating-Cash-Flow Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

117.45

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial							119.43	-	-	-	-

Competitive Comparison of RemeGen Co's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, RemeGen Co's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Price-to-Operating-Cash-Flow falls into.

RemeGen Co Price-to-Operating-Cash-Flow Calculation

RemeGen Co's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	12.32	/	-3.228
	=

RemeGen Co's Share Price of today is HK$12.32.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RemeGen Co's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-3.23.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

RemeGen Co Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Rongchang Holding Group Ltd.	2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership)	2103 Interests held jointly with another person
Yang Minhua	2103 Interests held jointly with another person
Xiong Xiaobin	2103 Interests held jointly with another person
Wen Qingkai	2103 Interests held jointly with another person
Wei Jianliang	2103 Interests held jointly with another person
Wang Xudong	2103 Interests held jointly with another person
Wang Weidong	2201 Interest of corporation controlled by you
Wang Liqiang	2103 Interests held jointly with another person
I-nova Limited	2101 Beneficial owner
Lin Jian	2103 Interests held jointly with another person
Fang Jianmin	2103 Interests held jointly with another person
Deng Yong	2103 Interests held jointly with another person
Morgan Stanley	2201 Interest of corporation controlled by you

RemeGen Co Headlines

No Headlines